U.S. FDA issues warning letter to Intas Pharma over manufacturing lapses
The U.S. FDA says the company's quality control unit failed to ensure its drug products meet specifications for "identity, strength, quality, and purity"
good manufacturing practices
December 2023
November 2023
Cipla stock tanks 8% after USFDA warning over issues at MP unit
Warning letter stresses data integrity issues at company embedded with product complaints and microbial contamination
